Coya Therapeutics collaborates with the Houston Methodist Research Institute (HMRI) to expand its existing research relationship. The research focuses on enhancing the functions of regulatory T cells (Tregs) to target severe neurodegenerative and autoimmune diseases. The Johnson Center for Cellular Therapeutics funds the research.

The research collaboration focuses on developing exosomes from patients' Tregs and analyzing and validating clinical biomarkers to track and manage diseases like amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson's. The agreement aims to combine COYA 301 (LD IL-2) with other relevant drug products to develop a unique approach to addressing the multifaceted pathophysiology of ailments and to form new strategies for future collaborations. 

Coya Therapeutics is a clinical-stage biotechnology company focused on developing treatments based on regulatory T cells (Tregs), targeting neurodegenerative, autoimmune, and metabolic diseases. The company's pipeline includes multiple Tregs-based programs, including its lead candidate, COYA 302, which combines COYA 301 (a low-dose IL-2) with CTLA4-Ig to enhance Treg function and reduce pro-inflammatory mediators, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and Alzheimer's disease​.